ArticleProceedings of the National Academy of Sciences of the United States of America2015
Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 200 citations in OpenAlex.
- A First-In-Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM-S401, a Novel siRNA-DegradaBALL Drug Targeting CTGF in Healthy Adults.Clinical and translational science · 2025Trial
- ESCRT-I complex enhances therapeutic efficacy of ASO drugs by regulating endosomal escape and glucose homeostasis.Molecular therapy. Nucleic acids · 2026Article
- Ionizable Cholesterol-Integrated Lipid Nanoparticles for Efficient siRNA Delivery to Solid Tumors.ChemMedChem · 2026Article
- Precision Nanotechnology: Revolutionizing Therapeutic Strategies Against Drug-Resistant Breast Cancer.Annals of biomedical engineering · 2026Review
- A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR.Nature communications · 2026Article
- Messenger RNA delivery to islet β cells using conjugated lipid nanoparticles.Cell reports. Medicine · 2026Article
- Endocytic Adaptor Proteins in Vascular Diseases: Critical Role of Intracellular Trafficking in Regulating Pathobiology of Vascular Disorders.Cardiology discovery · 2026Review
- Nanoparticle-delivered miR-486-5p inhibits HNanoscale advances · 2026Article
- Advances in Lipid-Polymer Hybrid Nanoparticles: Design Strategies, Functionalization, Oncological and Non-Oncological Clinical Prospects.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Self-Assembled Multilayered Concentric Supraparticle Architecture.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Bundling gold nanorods with RCA-produced DNA tape into an intelligently reconfigurable nanocluster bomb for multimodal precision cancer therapy.Materials today. Bio · 2025Article
- Emerging roles of prohibitins in cancer: an update.Cancer gene therapy · 2025Review
- Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives.Frontiers in genetics · 2025Review
- Nanoparticles Codelivering mRNA and SiRNA for Simultaneous Restoration and Silencing of Gene/Protein Expression In Vitro and In Vivo.ACS nanoscience Au · 2024Article
- Recent trends in the delivery of RNA drugs: Beyond the liver, more than vaccine.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2024Review
- Review
- Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation.Nanomedicine (London, England) · 2024Review
- Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- mRNA nanodelivery systems: targeting strategies and administration routes.Biomaterials research · 2023Review
- New insights into nanosystems for non-small-cell lung cancer: diagnosis and treatment.RSC advances · 2023Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 4 countries.
Funding
Abstract
RNA interference (RNAi) represents a promising strategy for identification and validation of putative therapeutic targets and for treatment of a myriad of important human diseases including cancer. However, the effective systemic in vivo delivery of small interfering RNA (siRNA) to tumors remains a formidable challenge. Using a robust self-assembly strategy, we develop a unique nanoparticle (NP) platform composed of a solid polymer/cationic lipid hybrid core and a lipid-poly(ethylene glycol) (lipid-PEG) shell for systemic siRNA delivery. The new generation lipid-polymer hybrid NPs are small and uniform, and can efficiently encapsulate siRNA and control its sustained release. They exhibit long blood circulation (t1/2 ∼ 8 h), high tumor accumulation, effective gene silencing, and negligible in vivo side effects. With this RNAi NP, we delineate and validate the therapeutic role of Prohibitin1 (PHB1), a target protein that has not been systemically evaluated in vivo due to the lack of specific and effective inhibitors, in treating non-small cell lung cancer (NSCLC) as evidenced by the drastic inhibition of tumor growth upon PHB1 silencing. Human tissue microarray analysis also reveals that high PHB1 tumor expression is associated with poorer overall survival in patients with NSCLC, further suggesting PHB1 as a therapeutic target. We expect this long-circulating RNAi NP platform to be of high interest for validating potential cancer targets in vivo and for the development of new cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.